Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA(TM) (bevacizumab-vikg)

Stock Information for Recon Technology Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Recon Technology Ltd.

Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering
Outlook Therapeutics Announces Proposed Public Offering
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA(TM) (bevacizumab gamma) in Switzerland
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.